Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
Fleroxacin Recombinant Mouse Monoclonal Antibody (1H10)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 1
Fleroxacin Antibody (MA566497) in SDS-PAGE
SDS-PAGE characterization of Fleroxacin under reducing conditions. Lane M: Protein marker (kDa); Lane FRX: Purified Fleroxacin Recombinant Monoclonal (Product # MA566497). Fleroxacin showing heavy chain (~50 kDa) and light chain (~25 kDa). Gels were stained with Coomassie Brilliant Blue R-456.
产品信息
MA566497
产品规格
种属反应
Chemical
宿主/亚型
Mouse
/ IgG
Expression System
CHO cells
分类
Recombinant Monoclonal
类型
Antibody
克隆号
1H10
抗原
Conjugate of FRX hapten and KLH.
偶联物
形式
Liquid
浓度
3.2 mg/mL
纯化类型
Protein G
保存液
PBS
内含物
0.09% sodium azide
保存条件
-20°C
运输条件
Ambient (domestic); Wet ice (international)
靶标信息
Fleroxacin is a second-generation broad-spectrum fluoroquinolone antibiotic, distinguished by its trifluorinated structure, which sets it apart from other fluoroquinolones like ciprofloxacin and ofloxacin. Its gene location and structure are not typically discussed in the context of biosimilars, as fleroxacin itself is a chemical compound rather than a biologic entity. Fleroxacin's long half-life allows for once-daily dosing, enhancing patient compliance. It has been investigated for its potential repositioning from an antibiotic to an anti-cancer agent, showing potentiating effects when combined with known anticancer drugs such as 5-fluorouracil against bladder cancer cells. The development and use of biosimilars in clinical practice aim to improve patient accessibility to modern medicines, providing similar efficacy and safety parameters as their reference drugs. Fleroxacin's improved photostability, solubility, and antimicrobial activity have been achieved through the synthesis of pharmaceutical salts, such as fleroxacin-D-tartaric acid, enhancing its therapeutic potential.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
